Novavax, Inc. (NVAX) Stock Score, Valuation & Financial Research
Novavax, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 47/100.
Quick answer for NVAX
Novavax, Inc. currently has a Wall Street Score of 47/100. The stored market price is $9.23. Its financial score is 36/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Novavax, Inc. does
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established
NVAX financial snapshot
- Wall Street Score:
- 47/100
- Current price:
- $9.23
- Market capitalization:
- $1.52B
- Revenue:
- $596.3M
- Net income:
- $-87.8M
- Free cash flow:
- $-250.2M
- Cash:
- $228.4M
- Total debt:
- $295.1M
- EPS:
- 2.72
- P/E ratio:
- 3.4x
- Financial score:
- 36/100
- Valuation score:
- 100/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is -0.5%.
- Free cash flow is $-250.2M, showing cash burn in the current stored period.
- The balance sheet shows $228.4M of cash versus $295.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NVAX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.